Market Place
Sourcing Support
Magenta hoists Dianthus onto its shoulders via reverse merger
04 May 2023 //
FIERCE BIOTECH
Magenta Therapeutics & Dianthus Announce Merger Agreement
03 May 2023 //
GLOBENEWSWIRE
Magenta sets up Dianthus merger in quick, ending trial due to patient death
03 May 2023 //
ENDPTS
Magenta Therapeutics Adopts Limited Duration Stockholder Rights Plan
31 Mar 2023 //
GLOBENEWSWIRE
Magenta CEO exits, 84% of staff let go as shuttering looms
09 Feb 2023 //
ENDPTS
Magenta Therapeutics to Explore Strategic Alternatives
02 Feb 2023 //
GLOBENEWSWIRE
Days after halting leukemia drug, Magenta to close its doors
02 Feb 2023 //
FIERCE BIOTECH
Magenta Therapeutics Voluntarily Pauses the MGTA-117 Phase 1/2 trial
26 Jan 2023 //
GLOBENEWSWIRE
Magenta Provides Update for MGTA-117 Phase 1/2 Dose Escalation Clinical Trial
20 Dec 2022 //
GLOBENEWSWIRE
Magenta halts group in leukemia trial after serious side effects
20 Dec 2022 //
FIERCEBIOTECH
Magenta Therapeutics to Host Conference Call and Webcast on Tuesday, Dec13, 2022
12 Dec 2022 //
GLOBENEWSWIRE
Magenta Therapeutics Presents Positive MGTA-117 Clinical Data at (ASH)
12 Dec 2022 //
GLOBENEWSWIRE
Magenta Therapeutics to Present Data at the 2022 (ASH) Annual Meeting
03 Nov 2022 //
GLOBENEWSWIRE
Magenta Reports Third Quarter Financial Results and Recent Program Highlights
03 Nov 2022 //
GLOBENEWSWIRE
Magenta to Participate in the Credit Suisse 31st Annual Healthcare Conference
01 Nov 2022 //
GLOBENEWSWIRE
Magenta Appoints Michael Vasconcelles, M.D. to the Board of Directors
17 Aug 2022 //
GLOBENEWSWIRE
Magenta Therapeutics Reports Second Quarter Financial Results
04 Aug 2022 //
GLOBENEWSWIRE
Magenta Tx to Participate in Panel Discussion at 2022 Wedbush Conference
02 Aug 2022 //
GLOBENEWSWIRE
Magenta Therapeutics Reports First Quarter Financial Results
16 May 2022 //
BUSINESSWIRE
Magenta feels the biotech blues, announces layoffs and clinical trial cuts
15 Apr 2022 //
ENDPTS
Magenta Therapeutics Reports Q4 and Full-Year 2021 Financial Results
08 Mar 2022 //
BUSINESSWIRE
Magenta Tx Highlights Pipeline Progress, Milestone Expectations for 2022
10 Jan 2022 //
BUSINESSWIRE
Start at the top’: Women in biotech on how to break down barriers in industry
29 Nov 2021 //
STATNEWS
Magenta nabs Constellation CMO after 5-month search, trial snag
04 Oct 2021 //
FIERCEBIOTECH
Magenta nabs Constellation CMO after 5-month search, trial snag
04 Oct 2021 //
FIERCEBIOTECH
FDA clears Magenta`s IND for MGTA-117 Targeted Conditioning Clinical Trial
15 Sep 2021 //
BIOSPACE
Magenta Therapeutics Reports Second Quarter Financial Results
05 Aug 2021 //
BUSINESSWIRE
Magenta slips after FDA hold on early-stage trial of MGTA-117 in AML, MDS
22 Jul 2021 //
FIRSTWORDPHARMA
FDA levels clinical hold on Magenta`s second lead drug
22 Jul 2021 //
ENDPTS
Magenta Therapeutics Announces Update on U.S. FDA INDA for MGTA-117
21 Jul 2021 //
BUSINESSWIRE
Moderna, Magenta ink agreement to distribute Moderna Covid-19 vaccine
16 Jun 2021 //
PHARMABIZ
Moderna and Magenta Partner to Distribute Moderna’s COVID-19 Vaccine
15 Jun 2021 //
BUSINESSWIRE
Magenta Therapeutics Appoints Thomas Beetham as Chief Legal Officer
14 Jun 2021 //
BUSINESSWIRE
Magenta`s R&D head hits the exit just weeks after reading out mid-stage data
27 May 2021 //
ENDPTS
Verily`s Onduo takes its virtual clinic into mental health
27 May 2021 //
FIERCEBIOTECH
Magenta Therapeutics Announces Positive Preliminary Results from Phase 2
12 May 2021 //
BUSINESSWIRE
Magenta Announces Positive Preliminary Results from Ph2 Trial of MGTA-145
12 May 2021 //
BUSINESSWIRE
Magenta Therapeutics Presents Final Phase 1 Results of MGTA-145
15 Mar 2021 //
BUSINESSWIRE
Magenta Presents Final Phase 1 Results of MGTA-145 Stem Cell Mobilization
15 Mar 2021 //
BUSINESSWIRE
MAGENTA HIGHLIGHTS RECENT PROGRESS AND EXPECTED TIMING OF 2021
11 Jan 2021 //
PRESS RELEASE
Magenta Announces Commencement of First Phase 2 Clinical Trial of MGTA-145
07 Dec 2020 //
BUSINESSWIRE
MAGENTA THERAPEUTICS ANNOUNCES COMMENCEMENT OF FIRST PHASE 2 CLINICAL TRIAL
07 Dec 2020 //
PRESS RELEASE
Magenta & bluebird bio Announce a Ph2 Trial Collaboration MGTA-145
04 Dec 2020 //
BUSINESSWIRE
Magenta & bluebird bio Announce a Phase 2 Clinical Trial Collaboratio MGTA-145
04 Dec 2020 //
BUSINESSWIRE
Magenta Announces Multiple Presentations Across Stem Cell Transplant Portfolio
04 Nov 2020 //
YAHOO
Magenta Announces Multiple Presentations Across Stem Cell Transplant Portfolio
04 Nov 2020 //
BUSINESSWIRE
Magenta nabs AbbVie alum as new CSO, while COO steps down
03 Sep 2020 //
FIERCE BIOTECH
Magenta Therapeutics Announces Closing of Public Offering Including Full Exercis
30 Jun 2020 //
BUSINESSWIRE
Magenta Therapeutics Announces Pricing of Public Offering
24 Jun 2020 //
BUSINESSWIRE
Magenta`s technology attracts another gene therapy developer
15 Jun 2020 //
BIOPHARMADIVE
Magenta Provides Portfolio Update: Stem Cell Mobilization & Conditioning
10 Jun 2020 //
BUSINESSWIRE
Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences
08 Jun 2020 //
BUSINESSWIRE
Magenta Therapeutics Presents Data Supporting Immune Reset for AD
04 Jun 2020 //
BUSINESSWIRE
Avrobio taps Magenta’s ADC for gene therapy conditioning
06 May 2020 //
BUSINESSWIRE
Magenta Therapeutics to Present Data from Across Portfolio at (ASGCT)
28 Apr 2020 //
BUSINESSWIRE
Magenta Therapeutics Names John Davis Jr., M.D., M.P.H, M.S., Head of R&D
17 Apr 2020 //
BUSINESSWIRE
Magenta Conditioning Lead Clinical Candidate MGTA-117
24 Feb 2020 //
PRESS RELEASE
Magenta Therapeutics Completes Dosing in Phase 1 MGTA-145 Trial
24 Feb 2020 //
BUSINESSWIRE
Magenta Therapeutics Announces Updated Phase 2 Data on MGTA-456 Cell Therapy
20 Feb 2020 //
BUSINESSWIRE
Magenta Therapeutics First Immune Reset Results with Antibody-Drug Conjugate
11 Nov 2019 //
BUSINESSWIRE
